Ironwood Pharmaceuticals Inc (IRWD):企業の財務・戦略的SWOT分析

◆英語タイトル:Ironwood Pharmaceuticals Inc (IRWD) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH130084FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:64
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥33,750見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥50,625見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Ironwood Pharmaceuticals Inc (IRWD) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Ironwood Pharmaceuticals Inc (Ironwood) discovers, develops and commercializes drugs for gastrointestinal disorders. Its marketed product include Linzess (linaclotide), an oral capsule for the treatment of irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) in adults. Ironwood also evaluates linaclotide in other indications, new formulations and in combination with other products in various GI conditions including IBS-C or FC in pediatrics. It is also advancing IW-3300, a guanylate cyclase-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/ bladder pain syndrome and endometriosis. Ironwood is headquartered in Cambridge, Massachusetts, the US.

Ironwood Pharmaceuticals Inc Key Recent Developments

Mar 30,2021: Ironwood Pharmaceuticals announces management changes
Feb 17,2021: Ironwood Pharmaceuticals reports fourth quarter and full year 2020 results exceeding or meeting full year 2020 financial guidance provides full year 2021 financial guidance
Feb 08,2021: Ironwood Pharmaceuticals announces CEO transition
Dec 03,2020: Ironwood Pharmaceuticals appoints Jay P. Shepard to Board of Directors
Nov 05,2020: Ironwood Pharmaceuticals reports strong third quarter 2020 results and increases full year 2020 financial guidance

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Ironwood Pharmaceuticals Inc – Key Facts
Ironwood Pharmaceuticals Inc – Key Employees
Ironwood Pharmaceuticals Inc – Key Employee Biographies
Ironwood Pharmaceuticals Inc – Major Products and Services
Ironwood Pharmaceuticals Inc – History
Ironwood Pharmaceuticals Inc – Company Statement
Ironwood Pharmaceuticals Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Ironwood Pharmaceuticals Inc – Business Description
Other Break-up: Collaborative Arrangements Revenue
Performance
Other Break-up: Product Revenue
Performance
Other Break-up: Sale of Active Pharmaceutical Ingredient
Performance
Ironwood Pharmaceuticals Inc – Corporate Strategy
Ironwood Pharmaceuticals Inc – SWOT Analysis
SWOT Analysis – Overview
Ironwood Pharmaceuticals Inc – Strengths
Ironwood Pharmaceuticals Inc – Weaknesses
Ironwood Pharmaceuticals Inc – Opportunities
Ironwood Pharmaceuticals Inc – Threats
Ironwood Pharmaceuticals Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Ironwood Pharmaceuticals Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 30, 2021: Ironwood Pharmaceuticals announces management changes
Feb 17, 2021: Ironwood Pharmaceuticals reports fourth quarter and full year 2020 results exceeding or meeting full year 2020 financial guidance provides full year 2021 financial guidance
Feb 08, 2021: Ironwood Pharmaceuticals announces CEO transition
Dec 03, 2020: Ironwood Pharmaceuticals appoints Jay P. Shepard to Board of Directors
Nov 05, 2020: Ironwood Pharmaceuticals appoints Alexander Denner, Ph.D., to Board of Directors
Nov 05, 2020: Ironwood Pharmaceuticals reports strong third quarter 2020 results and increases full year 2020 financial guidance
Sep 29, 2020: Ironwood to cut 100 jobs after digestive disease drug fails study
Aug 06, 2020: Ironwood Pharmaceuticals reports second quarter 2020 results; delivered GAAP net income of $25 million and adjusted EBITDA of $33 million
Mar 26, 2020: Ironwood Pharmaceuticals provides update on impact of COVID-19
Feb 13, 2020: Ironwood Pharmaceuticals reports strong fourth quarter and full year 2019 results, exceeding full year 2019 guidance; provides full year 2020 guidance
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Ironwood Pharmaceuticals Inc, Key Facts
Ironwood Pharmaceuticals Inc, Key Employees
Ironwood Pharmaceuticals Inc, Key Employee Biographies
Ironwood Pharmaceuticals Inc, Major Products and Services
Ironwood Pharmaceuticals Inc, History
Ironwood Pharmaceuticals Inc, Subsidiaries
Ironwood Pharmaceuticals Inc, Key Competitors
Ironwood Pharmaceuticals Inc, Ratios based on current share price
Ironwood Pharmaceuticals Inc, Annual Ratios
Ironwood Pharmaceuticals Inc, Annual Ratios (Cont...1)
Ironwood Pharmaceuticals Inc, Annual Ratios (Cont...2)
Ironwood Pharmaceuticals Inc, Interim Ratios
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Ironwood Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Ironwood Pharmaceuticals Inc (IRWD):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Mitsui-Soko Holdings Co Ltd (9302):企業の財務・戦略的SWOT分析
    Mitsui-Soko Holdings Co Ltd (9302) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • SGS SA (SGSN):電力:M&Aディール及び事業提携情報
    Summary SGS SA (SGS) is a provider of inspection, verification, testing, certification and quality assurance services. The company also provides risk management, consultancy, sustainability solutions and training services. SGS inspects, samples, analyzes, and monitors raw materials, components and p …
  • Liberty Mutual Holding Company Inc.:企業の戦略・SWOT・財務情報
    Liberty Mutual Holding Company Inc. - Strategy, SWOT and Corporate Finance Report Summary Liberty Mutual Holding Company Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Ornim Inc:医療機器:M&Aディール及び事業提携情報
    Summary Ornim Inc (Ornim) is a medical device company that specializes in clinical research, development and distribution of medical devices in the field of tissue and cerebral blood flow and perfusion, among others. The company’s c-FLOW is a continuous non-invasive monitor of deep tissue blood flow …
  • Trust International Insurance Co. P.L.C.
    Trust International Insurance Co. P.L.C. - Strategy, SWOT and Corporate Finance Report Summary Trust International Insurance Co. P.L.C. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • TransDigm Group Inc:企業の戦略・SWOT・財務分析
    TransDigm Group Inc - Strategy, SWOT and Corporate Finance Report Summary TransDigm Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Freudenberg & Co KG:企業の戦略的SWOT分析
    Freudenberg & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Edwards Lifesciences Corp (EW)-製薬・医療分野:企業M&A・提携分析
    Summary Edwards Lifesciences Corp (Edwards) is a global medical technology company, which focuses on the development, manufacture and marketing of products and technologies used for the treatment of structural heart disease and critical conditions. It develops and commercializes heart valve products …
  • Materialise NV (MTLS):企業の財務・戦略的SWOT分析
    Materialise NV (MTLS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Juwi Inc:電力:M&Aディール及び事業提携情報
    Summary Juwi Inc (Juwi), a subsidiary of juwi AG is a renewable energy company that operates wind and solar projects. The company’s services include development and acquisition, engineering, procurement, construction and operations and maintenance. Juwi's operations and maintenance services comprise …
  • Fujifilm Holdings Corporation (FUJIY):製薬・医療:M&Aディール及び事業提携情報
    Summary Fujifilm Holdings Corp (Fujifilm) sales and manufactures imaging systems and document solution equipment. The company’s major products are color films, color paper and chemicals, photofinishing equipment, electronic imaging and optical devices, TV camera lenses, security lenses, healthcare p …
  • Rubicon Genomics Inc:医療機器:M&Aディール及び事業提携情報
    Summary Rubicon Genomics Inc (Rubicon Genomics), a subsidiary of the Takara Bio Group is a provider of pre-analytical amplification technologies. The company offers various types of kits for whole genome sequencing (WGS), whole exome sequencing (WES), targeted sequencing, copy number variation (CNV) …
  • United Parcel Service Inc (UPS):企業の財務・戦略的SWOT分析
    United Parcel Service Inc (UPS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Macquarie Bank Ltd:企業のM&A・事業提携・投資動向
    Macquarie Bank Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Macquarie Bank Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Natsionalna Elektricheska Kompania EAD:企業の戦略的SWOT分析
    Natsionalna Elektricheska Kompania EAD - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and ma …
  • Karyopharm Therapeutics Inc (KPTI):企業の財務・戦略的SWOT分析
    Karyopharm Therapeutics Inc (KPTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Banque Marocaine du Commerce Exterieur SA:企業の戦略・SWOT・財務分析
    Banque Marocaine du Commerce Exterieur SA - Strategy, SWOT and Corporate Finance Report Summary Banque Marocaine du Commerce Exterieur SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Onconova Therapeutics Inc (ONTX):企業の財務・戦略的SWOT分析
    Onconova Therapeutics Inc (ONTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Cairn India Ltd (CAIRN)-石油・ガス分野:企業M&A・提携分析
    Summary Cairn India Limited (Cairn India) is an independent oil and gas company. It explores for, develops, and produces oil and natural gas. The company has varying working interests in India, Sri Lanka and South Africa. Its blocks are located in the basins of Barmer, Krishna- Godavari, the Palar-P …
  • SMC Corporation (6273):企業の財務・戦略的SWOT分析
    SMC Corporation (6273) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆